- Six oral and poster presentations will highlight breadth of
clinical program and potential utility of epcoritamab-bysp in
patients with difficult-to-treat lymphomas across multiple lines of
therapy and histologies where high unmet needs exist
- Results from two studies evaluating tisotumab vedotin in
patients with head and neck squamous cell carcinoma and recurrent
or metastatic cervical cancer accepted for oral and poster
presentations, respectively
- First presentation of Phase 2 study of acasunlimab (also
known as GEN1046/BNT311) in patients with previously treated
metastatic non-small cell lung cancer (mNSCLC)
Genmab A/S (Nasdaq: GMAB) announced today that
multiple abstracts evaluating epcoritamab, a T-cell engaging
bispecific antibody administered subcutaneously, tisotumab vedotin,
an antibody-drug conjugate (ADC), and acasunlimab (also known as
GEN1046/BNT311), an investigational bispecific antibody, will be
presented at the 2024 American Society of Clinical Oncology (ASCO)
Annual Meeting, being held in Chicago, IL and virtually, May
31-June 2, 2024.
“The data being presented this year at ASCO demonstrate Genmab’s
significant progress towards our mission to develop novel antibody
therapies with the goal of improving the lives of people impacted
by cancer,” said Dr. Judith Klimovsky, Executive Vice President and
Chief Development Officer of Genmab.
Presentations will include data from multiple clinical trials
evaluating the efficacy and safety of epcoritamab in a variety of
treatment settings and patient populations, including a rapid oral
presentation evaluating epcoritamab in combination with rituximab
and lenalidomide (R2) in patients with previously untreated
follicular lymphoma (FL) and a second rapid oral presentation
showcasing results from the pivotal and cycle 1 dose optimization
cohorts of EPCORE NHL-1 evaluating epcoritamab in patients with
relapsed/refractory (R/R) FL.
Data from the Phase 2 innovaTV 207 trial, evaluating tisotumab
vedotin in pretreated patients with relapsed/metastatic head and
neck squamous cell carcinoma will be presented during a rapid oral
session. Additionally, results from the Phase 3 innovaTV 301 trial
evaluating tisotumab vedotin in patients with recurrent or
metastatic cervical cancer with disease progression on or after
chemotherapy will be presented.
Finally, data from the Phase 2 clinical trial evaluating
acasunlimab as monotherapy and in combination with pembrolizumab in
patients with previously treated metastatic non-small cell lung
cancer (mNSCLC) will be presented for the first time during a
poster presentation.
The safety and efficacy of these investigational medicines
have not been established for these uses.
Virtual mid- to late-stage pipeline update at ASCO 2024
On Monday, June 3, at 9:00 AM CDT (10:00 AM EDT/4:00 PM CEST),
Genmab will host a review of data presented at ASCO from its mid-
to late-stage pipeline. The event will be virtual and webcast live.
Details, including the webcast link and registration will be
available on www.genmab.com. This meeting is not an official
program of the ASCO Annual Meeting.
All abstracts accepted for presentation have been published and
may be accessed online via the ASCO Meeting Library.
Abstracts accepted for presentation at ASCO:
Epcoritamab:
Abstract Number
Abstract Title
Type of Presentation
Date/Time of Presentation
7014
Epcoritamab with rituximab +
lenalidomide (R2) in previously untreated (1L) follicular lymphoma
(FL) and epcoritamab maintenance in FL: EPCORE NHL 2 arms 6 and
7
Rapid Oral
June 2, 4:30-6:00 PM CDT
7015
EPCORE NHL 1 follicular lymphoma
(FL) cycle (C) 1 optimization (OPT) cohort: Expanding the clinical
utility of epcoritamab in relapsed or refractory (R/R) FL
Rapid Oral
June 2, 4:30-6:00 PM CDT
7029
Subcutaneous Epcoritamab (SC
epcor) administered outpatient (outpt) for relapsed or refractory
(R/R) diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma
(FL): Results from Phase 2 EPCORE NHL-6
Poster
June 3, 9:00 AM-12:00 PM CDT
7032
Epcoritamab + R-DHAX/C in
transplant-eligible patients (pts) with high-risk relapsed or
refractory (R/R) diffuse large B-cell lymphoma (DLBCL)
Poster
June 3, 9:00 AM-12:00 PM CDT
7037
Subcutaneous epcoritamab + GemOx
in patients with relapsed or refractory DLBCL: Updated results from
EPCORE NHL-2
Poster
June 3, 9:00 AM-12:00 PM CDT
7039
Extended follow-up results beyond
2.5 years from the pivotal NHL-1 EPCORE trial: Subcutaneous
epcoritamab monotherapy in patients with relapsed/refractory large
B-cell lymphoma (R/R LBCL)
Poster
June 3, 9:00 AM-12:00 PM CDT
TPS7084
EPCORE FL-2: Phase 3 trial of
epcoritamab with rituximab and lenalidomide (R2) vs
chemoimmunotherapy or R2 in previously untreated follicular
lymphoma
Poster
June 3, 9:00 AM-12:00 PM CDT
Tisotumab Vedotin:
Abstract Number
Abstract Title
Type of Presentation
Date/Time of Presentation
6012
Tisotumab vedotin in head and
neck squamous cell carcinoma: updated analysis from innovaTV 207
Part C
Rapid Oral
June 3, 8:00-9:30 AM CDT
5531
Tisotumab vedotin in 2L/3L
recurrent or metastatic cervical cancer: subsequent therapy data
from ENGOT-cx12/GOG-3057/innovaTV 301
Poster
June 3, 9:00 AM-12:00 PM CDT
Acasunlimab:
Abstract Number
Abstract Title
Type of Presentation
Date/Time of Presentation
2533
Acasunlimab (DuoBody-PD-L1x4-1BB)
alone or in combination with pembrolizumab (pembro) in patients
(pts) with previously treated metastatic non-small cell lung cancer
(mNSCLC): initial results of a randomized, open-label, Phase 2
trial
Poster
June 1, 9:00 AM-12:00 PM CDT
About Epcoritamab Epcoritamab-bysp is an IgG1-bispecific
antibody created using Genmab's proprietary DuoBody® technology and
administered subcutaneously. Genmab's DuoBody-CD3 technology is
designed to direct cytotoxic T cells selectively to elicit an
immune response towards target cell types. Epcoritamab is designed
to simultaneously bind to CD3 on T-cells and CD20 on B-cells and
induces T-cell mediated killing of CD20+ cells.i Epcoritamab is
being co-developed by Genmab and AbbVie as part of the companies'
oncology collaboration.
Epcoritamab has received regulatory approval in certain lymphoma
indications in several territories. Use of epcoritamab in FL is not
approved in the U.S. or in the EU or in any other territory.
Epcoritamab is being co-developed by Genmab and AbbVie as part of
the companies' oncology collaboration. The companies will share
commercial responsibilities in the U.S. and Japan, with AbbVie
responsible for further global commercialization.
Genmab and AbbVie continue to evaluate the use of epcoritamab as
a monotherapy, and in combination, across lines of therapy in a
range of hematologic malignancies. This includes four ongoing phase
3, open-label, randomized trials including a trial evaluating
epcoritamab as a monotherapy in patients with R/R DLBCL compared to
investigators choice chemotherapy (NCT: 04628494), a trial
evaluating epcoritamab in combination with R-CHOP in adult
participants with newly diagnosed DLBCL (NCT: 05578976), a trial
evaluating epcoritamab in combination with rituximab and
lenalidomide in patients with R/R FL (NCT: 05409066), and a trial
evaluating epcoritamab in combination with rituximab and
lenalidomide (R2) compared to chemotherapy in patients with
previously untreated FL (NCT: 06191744). The safety and efficacy of
epcoritamab has not been established for these investigational
uses.
EPKINLY® (epcoritamab-bysp) U.S. IMPORTANT
SAFETY INFORMATION
Important Warnings—EPKINLY can cause serious side effects,
including:
- Cytokine release syndrome (CRS), which is common during
treatment with EPKINLY and can be serious or life-threatening. To
help reduce your risk of CRS, you may receive other medicines
before receiving EPKINLY and you will also be given smaller doses
of EPKINLY for the first 2 doses (called “step-up” dosing). Your
first full dose of EPKINLY will be given on day 15 of your first
cycle of treatment and you should be hospitalized for 24 hours
after due to risk of CRS and neurologic problems. If your dose of
EPKINLY is delayed for any reason, you may need to repeat the
step-up dosing schedule.
- Neurologic problems that can be life-threatening and
lead to death. Neurologic problems may happen days or weeks after
you receive EPKINLY.
Tell your healthcare provider or get medical help right
away if you develop a fever of 100.4°F (38°C) or higher;
dizziness or lightheadedness; trouble breathing; chills; fast
heartbeat; feeling anxious; headache; confusion; shaking (tremors);
problems with balance and movement, such as trouble walking;
trouble speaking or writing; confusion and disorientation;
drowsiness, tiredness or lack of energy; muscle weakness; seizures;
or memory loss. These may be symptoms of CRS or neurologic
problems. Do not drive or use heavy machinery or do other
dangerous activities if you have any symptoms that impair
consciousness until your symptoms go away.
EPKINLY can cause other serious side effects,
including:
- Infections that may lead to death. Tell your healthcare
provider right away if you develop any symptoms of infection during
treatment, including fever of 100.4°F (38°C) or higher, cough,
chest pain, tiredness, shortness of breath, painful rash, sore
throat, pain during urination, or feeling weak or generally
unwell.
- Low blood cell counts are common during treatment with
EPKINLY and can be serious or severe. Your healthcare provider will
check your blood cell counts during treatment. EPKINLY may cause
low blood cell counts, including low white blood cells
(neutropenia), which can increase your risk for infection; low red
blood cells (anemia), which can cause tiredness and shortness of
breath; and low platelets (thrombocytopenia), which can cause
bruising or bleeding problems.
Your healthcare provider will monitor you for symptoms of CRS,
neurologic problems, infections, and low blood cell counts during
treatment with EPKINLY. Your healthcare provider may temporarily
stop or completely stop treatment with EPKINLY if you develop
certain side effects.
Before you receive EPKINLY, tell your healthcare provider
about all your medical conditions, including if you have an
infection, are pregnant or plan to become pregnant, or are
breastfeeding or plan to breastfeed. If you receive EPKINLY while
pregnant, it may harm your unborn baby. If you are a female who
can become pregnant, your healthcare provider should do a
pregnancy test before you start treatment with EPKINLY and you
should use effective birth control (contraception) during treatment
and for 4 months after your last dose of EPKINLY. Tell your
healthcare provider if you become pregnant or think that you may be
pregnant during treatment with EPKINLY. Do not breastfeed during
treatment with EPKINLY and for 4 months after your last dose of
EPKINLY.
The most common side effects of EPKINLY include CRS,
tiredness, muscle and bone pain, injection site reactions, fever,
stomach-area (abdominal) pain, nausea, and diarrhea. These are not
all the possible side effects of EPKINLY. Call your doctor for
medical advice about side effects.
You are encouraged to report side effects to the FDA at (800)
FDA-1088 or www.fda.gov/medwatch or to Genmab US, Inc. at
1-855-4GENMAB (1-855-443-6622).
Please see Medication Guide, including Important Warnings.
About Tisotumab Vedotin Tisotumab vedotin is an
antibody-drug conjugate (ADC) composed of Genmab’s human monoclonal
antibody directed to tissue factor (TF) and Pfizer’s ADC technology
that utilizes a protease-cleavable linker that covalently attaches
the microtubule-disrupting agent monomethyl auristatin E (MMAE) to
the antibody. Nonclinical data suggest that the anticancer activity
of tisotumab vedotin is due to the binding of the ADC to
TF-expressing cancer cells, followed by internalization of the
ADC-TF complex, and release of MMAE via proteolytic cleavage. MMAE
disrupts the microtubule network of actively dividing cells,
leading to cell cycle arrest and apoptotic cell death. In vitro,
tisotumab vedotin also mediates antibody-dependent cellular
phagocytosis and antibody-dependent cellular cytotoxicity.
Tisotumab vedotin is co-owned by Genmab and Pfizer, under an
agreement in which the companies share costs and profits for the
product on a 50:50 basis.
Tisotumab vedotin has received full approval by the U.S. FDA for
the treatment of adult patients with recurrent or metastatic
cervical cancer (r/mCC) with disease progression on or after
chemotherapy. Tisotumab vedotin in HNSCC is not approved in any
country, including the U.S. and the EU.
TIVDAK® (tisotumab vedotin-tftv) U.S. IMPORTANT SAFETY
INFORMATION
Indication TIVDAK is indicated for the treatment of adult
patients with recurrent or metastatic cervical cancer (r/mCC) with
disease progression on or after chemotherapy.
Important Safety Information
BOXED WARNING: OCULAR TOXICITY
TIVDAK can cause severe ocular toxicities resulting in changes
in vision, including severe vision loss, and corneal ulceration.
Conduct an ophthalmic exam, including an assessment of ocular
symptoms, visual acuity, and slit lamp exam of the anterior segment
of the eye prior to initiation of TIVDAK, prior to every cycle for
the first nine cycles, and as clinically indicated. Adhere to the
required premedication and eye care before, during, and after
infusion. Withhold TIVDAK until improvement and resume, reduce the
dose, or permanently discontinue, based on severity.
Warnings and Precautions
Ocular adverse reactions: TIVDAK can cause severe ocular adverse
reactions, including conjunctivitis, keratopathy (keratitis,
punctate keratitis, and ulcerative keratitis), and dry eye
(increased lacrimation, eye pain, eye discharge, pruritus,
irritation, and foreign body sensation), that may lead to changes
in vision and/or corneal ulceration.
Ocular adverse reactions occurred in 55% of patients with
cervical cancer treated with TIVDAK across clinical trials. The
most common were conjunctivitis (32%), dry eye (24%), keratopathy
(17%), and blepharitis (5%). Grade 3 ocular adverse reactions
occurred in 3.3% of patients, including severe ulcerative keratitis
in 1.2% of patients. Nine patients (2.1%) experienced ulcerative
keratitis (including one with perforation requiring corneal
transplantation), six (1.4%) conjunctival ulcer, four (0.9%)
corneal erosion, two (0.5%) conjunctival erosion, and two (0.5%)
symblepharon.
In innovaTV 301, 8 patients (3.2%) experienced delayed ocular
adverse reactions occurring more than 30 days after discontinuation
of TIVDAK. These adverse reactions included 3 patients with
ulcerative keratitis, and one patient (each) with keratitis,
punctate keratitis and corneal erosion, blepharitis and
conjunctival hyperemia, conjunctival scar, and conjunctivitis and
xerophthalmia.
Refer patients to an eye care provider to conduct an ophthalmic
exam prior to initiation of TIVDAK, prior to every cycle for the
first nine cycles, and as clinically indicated. The exam should
include visual acuity, slit lamp exam of the anterior segment of
the eye, and an assessment of normal eye movement and ocular signs
or symptoms which include dry or irritated eyes, eye secretions, or
blurry vision.
Adhere to the required premedication and eye care before,
during, and after infusion to reduce the risk of ocular adverse
reactions. Monitor for ocular toxicity and promptly refer patients
to an eye care provider for any new or worsening ocular signs and
symptoms. Withhold, reduce, or permanently discontinue TIVDAK based
on the severity or persistence of the ocular adverse reaction.
Peripheral Neuropathy (PN) occurred in 39% of cervical cancer
patients treated with TIVDAK across clinical trials; 6% of patients
experienced Grade 3 PN. PN adverse reactions included peripheral
sensory neuropathy (23%), PN (5%), paresthesia (3.8%), peripheral
sensorimotor neuropathy (3.3%), muscular weakness (2.8%), and
peripheral motor neuropathy (2.4%). One patient with another tumor
type treated with TIVDAK at the recommended dose developed
Guillain- Barre syndrome.
Monitor patients for signs and symptoms of neuropathy such as
paresthesia, tingling or a burning sensation, neuropathic pain,
muscle weakness, or dysesthesia. For new or worsening PN, withhold,
then dose reduce, or permanently discontinue TIVDAK based on the
severity of PN.
Hemorrhage occurred in 51% of cervical cancer patients treated
with TIVDAK across clinical trials. The most common all grade
hemorrhage adverse reaction was epistaxis (33%). Grade 3 hemorrhage
occurred in 4% of patients.
Monitor patients for pulmonary symptoms of pneumonitis. Symptoms
may include hypoxia, cough, dyspnea or interstitial infiltrates on
radiologic exams. Infectious, neoplastic, and other causes for such
symptoms should be excluded through appropriate investigations.
Withhold TIVDAK for patients who develop persistent or recurrent
Grade 2 pneumonitis and consider dose reduction. Permanently
discontinue TIVDAK in all patients with Grade 3 or 4
pneumonitis.
Pneumonitis that is severe, life-threatening, or fatal can occur
in patients treated with antibody-drug conjugates containing
vedotin, including TIVDAK. Among cervical cancer patients treated
with TIVDAK across clinical trials, 4 patients (0.9%) experienced
pneumonitis, including 1 patient who had a fatal outcome.
Monitor patients for pulmonary symptoms of pneumonitis. Symptoms
may include hypoxia, cough, dyspnea or interstitial infiltrates on
radiologic exams. Infectious, neoplastic, and other causes for
symptoms should be excluded through appropriate investigations.
Withhold TIVDAK for patients who develop persistent or recurrent
Grade 2 pneumonitis and consider dose reduction. Permanently
discontinue TIVDAK in all patients with Grade 3 or 4
pneumonitis.
Severe cutaneous adverse reactions (SCAR), including events of
fatal or life-threatening Stevens-Johnson syndrome (SJS), can occur
in patients treated with TIVDAK. SCAR occurred in 1.6% of cervical
cancer patients treated with TIVDAK across clinical trials. Grade
≥3 SCAR occurred in 0.5% of patients, including 1 patient who had a
fatal outcome.
Monitor patients for signs or symptoms of SCAR, which include
target lesions, worsening skin reactions, blistering or peeling of
the skin, painful sores in mouth, nose, throat, or genital area,
fever or flu-like symptoms, and swollen lymph nodes. If signs or
symptoms of SCAR occur, withhold TIVDAK until the etiology of the
reaction has been determined. Early consultation with a specialist
is recommended to ensure greater diagnostic accuracy and
appropriate management. Permanently discontinue TIVDAK for
confirmed Grade 3 or 4 SCAR, including SJS.
Embryo-fetal toxicity: TIVDAK can cause fetal harm when
administered to a pregnant woman. Advise patients of the potential
risk to a fetus. Advise females of reproductive potential to use
effective contraception during treatment with TIVDAK and for 2
months after the last dose. Advise male patients with female
partners of reproductive potential to use effective contraception
during treatment with TIVDAK and for 4 months after the last
dose.
Adverse Reactions
Across clinical trials of TIVDAK in 425 patients with r/mCC, the
most common (≥25%) adverse reactions, including laboratory
abnormalities, were hemoglobin decreased (45%), PN (39%),
conjunctival adverse reactions (38%), nausea (37%), fatigue (36%),
aspartate aminotransferase increased (33%), epistaxis (33%),
alopecia (31%), alanine aminotransferase increased (30%), and
hemorrhage (28%).
innovaTV 301 Study: 250 patients with r/mCC with disease
progression on or after systemic therapy
Serious adverse reactions occurred in 33% of patients
receiving TIVDAK; the most common (≥2%) were urinary tract
infection (4.8%), small intestinal obstruction (2.4%), sepsis,
abdominal pain, and hemorrhage (each 2%). Fatal adverse
reactions occurred in 1.6% of patients who received TIVDAK,
including acute kidney injury, pneumonia, sepsis, and SJS (each
0.4%).
Adverse reactions leading to permanent discontinuation
occurred in 15% of patients receiving TIVDAK; the most common (≥3%)
were PN and ocular adverse reactions (each 6%). Adverse
reactions leading to dose interruption occurred in 39% of
patients receiving TIVDAK; the most common (≥3%) were ocular
adverse reactions (16%) and PN (6%). Adverse reactions leading
to dose reduction occurred in 30% of patients receiving TIVDAK;
the most common (≥3%) were PN and ocular adverse reactions (each
10%). The ocular adverse reactions included conjunctival disorders
(4.8%), keratopathy (4%), and dry eye (0.8%).
innovaTV 204 Study: 101 patients with r/mCC with disease
progression on or after chemotherapy
Serious adverse reactions occurred in 43% of patients;
the most common (≥3%) were ileus (6%), hemorrhage (5%), pneumonia
(4%), PN, sepsis, constipation, and pyrexia (each 3%). Fatal
adverse reactions occurred in 4% of patients who received
TIVDAK, including septic shock, pneumonitis, sudden death, and
multisystem organ failure (each 1%).
Adverse reactions leading to permanent discontinuation
occurred in 13% of patients receiving TIVDAK; the most common (≥3%)
were PN (5%) and corneal adverse reactions (4%). Adverse
reactions leading to dose interruption occurred in 47% of
patients; the most common (≥3%) were PN (8%), conjunctival adverse
reactions, and hemorrhage (each 4%). Adverse reactions leading
to dose reduction occurred in 23% of patients; the most common
(≥3%) were conjunctival adverse reactions (9%) and corneal adverse
reactions (8%).
Drug Interactions
Strong CYP3A4 inhibitors: Concomitant use with strong CYP3A4
inhibitors may increase unconjugated monomethyl auristatin E (MMAE)
exposure, which may increase the risk of TIVDAK adverse reactions.
Closely monitor patients for TIVDAK adverse reactions.
Use in Specific Populations
Moderate or severe hepatic impairment: MMAE exposure and adverse
reactions are increased. Avoid use.
Lactation: Advise lactating women not to breastfeed during
TIVDAK treatment and for at least 3 weeks after the last dose.
Please see full prescribing information, including BOXED WARNING
for TIVDAK here.
About Acasunlimab (GEN1046/BNT311) Acasunlimab
(GEN1046/BNT311) is an investigational PD-L1x4-1BB bispecific
antibody fusing Genmab's proprietary DuoBody® technology platform
and BioNTech’s proprietary immunomodulatory antibodies. Acasunlimab
is designed to elicit an antitumor response via conditional
activation of 4-1BB on T cells and natural killer (NK) cells, which
is strictly dependent on simultaneous binding of the PD-L1 arm.
Acasunlimab is being developed in collaboration with BioNTech SE
under a license and collaboration agreement and is currently in
Phase 2 of development.
Please visit www.clinicaltrials.gov for more information about
Genmab’s clinical trials.
About Genmab Genmab is an international biotechnology
company with a core purpose of guiding its unstoppable team to
strive toward improving the lives of patients with innovative and
differentiated antibody therapeutics. For 25 years, its passionate,
innovative and collaborative team has invented next-generation
antibody technology platforms and leveraged translational,
quantitative and data sciences, resulting in a proprietary pipeline
including bispecific T-cell engagers, antibody-drug conjugates,
next-generation immune checkpoint modulators and effector
function-enhanced antibodies. By 2030, Genmab’s vision is to
transform the lives of people with cancer and other serious
diseases with knock-your-socks-off (KYSO®) antibody medicines.
Established in 1999, Genmab is headquartered in Copenhagen,
Denmark, with international presence across North America, Europe
and Asia Pacific. For more information, please visit Genmab.com and
follow us on LinkedIn and X.
This Media Release contains forward looking statements. The
words “believe”, “expect”, “anticipate”, “intend” and “plan” and
similar expressions identify forward looking statements. Actual
results or performance may differ materially from any future
results or performance expressed or implied by such statements. The
important factors that could cause our actual results or
performance to differ materially include, among others, risks
associated with pre-clinical and clinical development of products,
uncertainties related to the outcome and conduct of clinical trials
including unforeseen safety issues, uncertainties related to
product manufacturing, the lack of market acceptance of our
products, our inability to manage growth, the competitive
environment in relation to our business area and markets, our
inability to attract and retain suitably qualified personnel, the
unenforceability or lack of protection of our patents and
proprietary rights, our relationships with affiliated entities,
changes and developments in technology which may render our
products or technologies obsolete, and other factors. For a further
discussion of these risks, please refer to the risk management
sections in Genmab’s most recent financial reports, which are
available on www.genmab.com and the risk factors included in
Genmab’s most recent Annual Report on Form 20-F and other filings
with the U.S. Securities and Exchange Commission (SEC), which are
available at www.sec.gov. Genmab does not undertake any obligation
to update or revise forward looking statements in this Media
Release nor to confirm such statements to reflect subsequent events
or circumstances after the date made or in relation to actual
results, unless required by law.
Genmab A/S and/or its subsidiaries own the following trademarks:
Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the
Y-shaped Genmab logo®; HuMax®; DuoBody®; DuoBody in combination
with the DuoBody logo®; HexaBody®; HexaBody in combination with the
HexaBody logo®; DuoHexaBody® and HexElect®. EPKINLY® and EPCORE®
are owned by AbbVie Biotechnology Ltd.
__________________________________ i Engelberts et al.
"DuoBody-CD3xCD20 induces potent T-cell-mediated killing of
malignant B cells in preclinical models and provides opportunities
for subcutaneous dosing." EBioMedicine. 2020;52:102625. DOI:
10.1016/j.ebiom.2019.102625
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240523620002/en/
David Freundel, Senior Director, Product Communications T: +1
609 430 2481; E: dafr@genmab.com
Andrew Carlsen, Vice President, Head of Investor Relations T:
+45 3377 9558; E: acn@genmab.com
Genmab AS (NASDAQ:GMAB)
Gráfico Histórico do Ativo
De Dez 2024 até Jan 2025
Genmab AS (NASDAQ:GMAB)
Gráfico Histórico do Ativo
De Jan 2024 até Jan 2025
